Floatz logo

Rapamycin

Estrogen Receptor Positive

Roswell Park Cancer InstitutePhase 1Dormant
CC
46/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
32/ 100
Competitive Position
89/ 100

Competitive context

77 Active assets in the Estrogen Receptor Positive cohort.

Asset / SponsorPhaseRating
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BBB
EXEMESTANE
National Cancer Institute (NCI)
Phase 4BBB
Everolimus
UNC Lineberger Comprehensive Cancer Center
Phase 4BBB
TAMOXIFEN
Dana-Farber Cancer Institute
Phase 4BB
Giredestrant
Hoffmann-La Roche
Phase 3BB

View all 50 →

Same molecule, other indications

Rapamycin is also rated in:

tuberous sclerosisDormant
BBB
Indicative ·
73 / 100
View asset →
disease related to transplantationDormant
BBB
Indicative ·
72 / 100
View asset →
myelodysplastic/myeloproliferative neoplasmDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →